BeOne Medicines AG (HKG:6160)
176.80
+1.70 (0.97%)
May 29, 2026, 4:08 PM HKT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 1.51B CNY in the quarter ending March 31, 2026, with 35.46% growth. This brings the company's revenue in the last twelve months to 5.74B, up 37.44% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of 5.34B with 40.23% growth.
Revenue (ttm)
5.74B CNY
Revenue Growth
+37.44%
P/S Ratio
5.61
Revenue / Employee
478.27K CNY
Employees
12,000
Market Cap
250.87B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.84B |
| Akeso | 3.40B |
BeOne Medicines AG News
- 2 days ago - BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 - Business Wire
- 3 days ago - BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results - GuruFocus
- 3 days ago - BeOne Medicines’ combination shows improved survival in adenocarcinoma - TheFly
- 3 days ago - BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 - Business Wire
- 5 days ago - BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 9 days ago - China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index - South China Morning Post
- 10 days ago - BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Business Wire
- 11 days ago - BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard - Business Wire